Moleculin Biotech MBRX 深 沪
等待开盘 12-15 09:30:00 美东时间
4.98
-0.020
-0.40%
华盛通- 最 高5.20
- 今 开5.06
- 成交量 19.39万股
- 最 低 4.75
- 昨 收 5.00
- 总市值 1027.87万
- 52周最高 91.2475
- 市盈率 静 --
- 换手率 9.39%
- 52周最低 4.75
- 委 比 -52.09%
- 总股本 206.40万
- 历史最高 21555.00
- 量 比 0.23
- 振 幅 9.00%
- 历史最低 4.75
- 每 手 1
- 风险率 12.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
12-12 10:24
Moleculin Biotech Enters Inducement Offer Agreements
Moleculin Biotech ( ($MBRX) ) has shared an announcement. On December 9, 2025, ...
12-11 06:17
Moleculin announces exercise of warrants for $6.8M
Moleculin Biotech (MBRX) said on Wednesday that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain warrants to purchase up to an aggreg...
12-10 22:07
Moleculin Biotech Raises $6.5M From Immediate Exercise Of 1,044,329 Warrants At $6.63 And $6.3219, Issues 2.61M New Warrants At $6.63
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has
12-10 21:34
Moleculin Biotech Partners With CIC biomaGUNE To Preclinically Test Annamycin For Glioblastoma Treatment
Investigator-Initiated Preclinical studies at CIC biomaGUNE aimed at combatting Glioblastoma Multiforme Research will evaluate effects of intra-arterial delivery of AnnamycinHOUSTON, Dec. 08, 2025 (GLOBE NEWSWIRE)
12-08 21:21
Moleculin Announces New Annamycin Collaboration in Brain Tumors
Moleculin Biotech和CIC biomaGUNE合作开展用于治疗胶质母细胞瘤的Annamycin临床前研究，探索其在脑肿瘤中的应用潜力，评估血管内给药效果。该药物在治疗急性髓性白血病和软组织肉瘤中已展现潜力，针对GBM的NCT06788756试验正在进行中。通过合作，Moleculin旨在解决GBM治疗中的药物递送和耐药性难题，提供更多治疗选择。
12-08 13:21
Moleculin Announces 1-For-25 Reverse Stock Split, Effective December 1
Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State ofMoleculin Biotech, Inc., (NASDAQ:MBRX</
11-26 22:01
Moleculin to Participate in the Virtual Investor Closing Bell Series
Moleculin Biotech, Inc. announced that its CEO, Walter Klemp, will participate in the Virtual Investor Closing Bell Series on December 2, 2025, at 4:00 PM ET. During the event, Klemp will provide a corporate overview, business outlook, and answer investor questions. The event will be live streamed on the Company's website, with a replay available for 90 days. Moleculin is a late-stage pharmaceutical company developing treatments for hard-to-treat...
11-26 14:15
Moleculin Announces Reverse Stock Split
Moleculin Biotech, Inc. (MBRX) announced a 1-for-25 reverse stock split effective December 1, 2025. This will reduce outstanding shares from approximately 51.7 million to 2.1 million, with no fractional shares issued; instead, cash payments will be made for fractional entitlements. The company, focused on developing therapeutics for hard-to-treat cancers and viruses, is in Phase 3 clinical trials for its lead drug, Annamycin, targeting relapsed o...
11-26 14:00
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Advanced Biomed (NASDAQ:ADVB) stock rose 29.6% to $0.48 during Monday'...
11-25 01:05
